Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin et al. · Leukemia · 2002 · 905 citations

Medicine, Molecular Biology, Molecular Genetics +11

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations

Medicine, Molecular Biology, Oncology +15

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Joerg Hasford, Michele Baccarani, Verena Hoffmann et al. · Blood · 2011 · 497 citations · Full text

Life Sciences, Biostatistics, Oncology +13